Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors
Jean‐Charles Soria(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Luca Gianni(IRCCS Ospedale San Raffaele), Nathalie Lassau(Université Paris-Sud), E. Borghi(Sanofi (France)), Antonella Perotti(European Institute of Oncology), Christophe Massard(Institut Gustave Roussy), C. Sessa(Hospital Clínico Universitario de Valencia), Jean‐Pierre Armand(Institut Curie), Françoise Farace(Inserm)
Cited by 8
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664